US Press Releases - Archive
Oncopeptides’ PEPAXTO® Receives a Permanent J-Code, Clarifying Reimbursement Processes in Hospital Outpatient and Physician Office Settings of Care
August 16, 2021
BOSTON— August 16, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announc...
Oncopeptides’ PEPAXTO ® Receives a Specific C-Code and Pass-Through Payment Status Further Streamlining Reimbursement in Hospital Sites of Care
July 13, 2021
BOSTON— July 13, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced...
Oncopeptides shares updated results from the phase 3 OCEAN study based upon further analysis
July 8, 2021
--
Phase 3 OCEAN study demonstrates that melphalan flufenamide is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma
May 26, 2021
--
Oncopeptides announces three abstracts accepted by the 2021 American Society of Clinical Oncology
May 19, 2021
WALTHAM — May 19, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announce...
Oncopeptides Completes Patient Enrollment in Phase 2 PORT Study
May 5, 2021
WALTHAM —May 5, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced ...
Oncopeptides Announces National Comprehensive Cancer Network® Adds PEPAXTO® (melphalan flufenamide) to Its Multiple Myeloma Clinical Practice Guidelines
March 22, 2021
--
Oncopeptides Announces Commercial Availability of PEPAXTO® (melphalan flufenamide)
March 15, 2021
--